Specializing in critical care and parenteral nutrition, the company is involved in the treatment of rare diseases, with one orphan drug designation and active initiatives in eight rare conditions.
1
Orphan Designations
44
FDA Approvals
8
Rare Diseases
0
News Articles
| Disease | Drug(s) | Designation | Approved |
|---|---|---|---|
| congenital secretory sodium diarrhea 8 | Omegaven | Orphan Designation | - |
| diarrhea 12, with microvillus atrophy | Omegaven | Orphan Designation | - |
| diarrhea 14, congenital | Omegaven | Orphan Designation | - |
| diarrhea 15, congenital | Omegaven | Orphan Designation | - |
| long chain fatty acids, defect in transport of | Omegaven | Orphan Designation | - |
| neurodegeneration with brain iron accumulation 7 | Omegaven | Orphan Designation | - |
| parenteral nutrition-associated cholestasis | Omegaven | Orphan Designation | - |
| peroxisome biogenesis disorder 4A (Zellweger) | Omegaven | Orphan Designation | - |